The intended audience for this educational initiative is gastroenterologists and hepatologists.
The goal of this program is to improve the knowledge and competence of learners on the pathophysiology of NASH, the interplay between NASH and other components of metabolic syndrome, the importance of early intervention in NASH, emerging metabolic therapies for NASH treatment, and how to develop patient-personalized multidisciplinary treatment plans in effort to optimize treatment for patients with NASH.
Upon completion of this activity, participants should be able to:
Determine appropriate strategies for early intervention and treatment in patients with NASH.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC
Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom
Stephen A. Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC: researcher: Akero, Axcella Health, Cirius, CiVi Biopharma, Cymabay, Enyo Pharma SA, Galectin, Galmed Research & Development, Genfit Corp, Gilead Sciences, Hepion, Hightide, Intercept, Madrigal, Metacrine, NGM Biopharmaceuticals, Northsea Therapeutics, Novartis, Novo Nordisk, Poxel, Sagimet Biosciences, Viking; consultant/advisor: 89Bio, AgomAB, Akero, Alentis Therapeutics AG, Altimmune, Arrowhead, Axcella Health, Boston Pharmaceuticals, B Riley FBR, BVF Partners LP, Canfite, Chronwell, CiVi, Corcept, Cymabay, Echosens North America, Enyo Pharma, Fibronostics, Foresite Labs, Fortress Biotech, Galectin, Galmed Research, Genfit Corp, Gilead Sciences, GNS, Hepion, Hightide Therapeutics, HistoIndex PTE LTD, Indalo, Inipharm, Intercept, Ionis, Kowa Research Institute, Madrigal, Medpace, Metacrine, Microba, NGM Biopharmaceuticals, Northsea Therapeutics, Novo Nordisk, Nutrasource, PathAi, Perspectum Diagnostics, Piper Sandler, Poxer, Prometic Pharma, Ridgeline, Sagimet, Sonic Incytes Medical Corp, Terns, Viking Therapeutics; stock/stock options: Akero Therapeutics, Chronwell, Cirius Therapeutics, Galectin Therapeutics, Genfit Corp, Hepion, HistoIndex, Metacrine, NGM Biopharmaceuticals, Northsea Therapeutics B.V, Sonic Incytes Medical Corp.
Brent A. Tetri, MD
Professor of Internal Medicine
Division of Gastroenterology and Hepatology
St. Louis University School of Medicine
St. Louis, Missouri
Brent Tetri, MD: consultant/advisor: 89Bio, Akero, Arrowhead, Boehringer Ingelheim, Bristol-Myers Squibb, Durect, GlaxoSmithKline, Glympse, Hepeon, High Tide, HistoIndex, Labcorp, LG Chem, Madrigal, Merck, Sagimet, Senseion, Target RWE; stock/stock options: HepGene, HeptaBio; researcher (paid to institution): Bristol-Myers Squibb, HighTide, Intercept, Inventiva, Madrigal.
The planners and content peer reviewers from the Potomac Center for Medical Education, Rockpointe, and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 19, 2023, through July 18, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation Statement
The Potomac Center for Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Designation Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To recieve CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.